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ABSTRACT
Objective: In addition to the most common somatic lung cancer mutations (i. e., 
KRAS and EGFR mutations), other genes may harbor mutations that could be relevant 
for lung cancer. We defined BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and 
RET mutations as “niche” mutations and analyzed. The aim of this retrospective cohort 
study was to assess the differences in the overall survival (OS) of patients with lung 
adenocarcinoma harboring niche somatic mutations.
Results: Data were gathered for 252 patients. Mutations were observed in all 
genes studied, except c-MET, DDR2, MAP2K1, and RET. The multivariable analysis 
showed that 1) niche mutations had a higher mortality than EGFR mutations (HR = 2.3; 
95% CI = 1.2–4.4; p = 0.009); 2) KRAS mutations had a higher mortality than EGFR 
mutations (HR = 2.5; 95% CI = 1.4–4.5; p = 0.003); 3) niche mutations presented a 
similar mortality to KRAS mutations (HR = 0.9; 95% CI = 0.6–1.5; p = 0.797).
Methods: Three cohorts of mutations were selected from patients with lung 
adenocarcinoma and their OS was compared. Mutations that were searched for, were 
1) BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET; 2) K-RAS; and 3) 
EGFR. Differences in OS between these three cohorts were assessed by means of a 
multivariable Cox model that adjusted for age, sex, smoking habits, clinical stages, 
and treatments.
Conclusions: Niche mutations exhibited an increased risk of death when compared 
with EGFR mutations and a similar risk of death when compared with KRAS mutations.
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INTRODUCTION
In the last century, carcinoma of the lung has 
progressed from an uncommon and obscure disease 
to the most common cancer in the world, and the most 
common cause of death from cancer. In 2018, new cases 
of lung cancer in the US were estimated at 121,680 for 
men and at 112,350 for women, for a total of 234,030 
cases, representing the equivalent of 641 cases of lung 
cancer diagnosed each day [1, 2]. Many gene mutations 
have previously been identified in several solid tumors 
[3, 4]. For lung cancer, in particular, the most common 
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mutations found are in the epidermal growth factor 
receptor (EGFR) gene and the K-Raf kinase gene family 
(KRAS) [5]. In addition to these somatic mutations, which 
are the most frequent, other mutations in several genes 
have been discovered, including BRAF, c-MET, DDR2, 
HER2, MAP2K1, NRAS, PIK3CA, and RET mutations 
[6, 7]. The main feature that characterizes these “niche” 
mutations is their low prevalence in the population of 
patients with lung cancer when compared with KRAS and 
EGFR. In the present study, we identified these “niche 
mutations” on the basis of a population prevalence that 
was equal to or less than 10% based on literature data 
[8–10]. In particular, according to recently published 
data concerning 14 healthcare institutions in the US, the 
prevalence for these mutations was as follows: KRAS 
25%, EGFR 23%, HER2 2.7%, BRAF 2.6%, PIK3CA 
0.8%, NRAS 0.7%, c-MET 0.7%, and MAP2K1 0.3% 
[8]. Moreover, the prevalence of the RET mutation in 
adenocarcinoma was estimated to be 1.7% [9], and the 
prevalence of DDR2 mutation in lung cancer was 2.2% 
[3, 10]. Overall, the KRAS mutation was considered to be 
the most lethal mutation, exhibiting the worst prognosis 
[3–5]. Nevertheless, the potential aggressiveness of niche 
mutations remains unclear [6, 8].
With regard to treatment, discoveries of gene 
mutations have allowed the development of targeted 
therapies, which are considered more effective for survival 
than chemotherapy in patients with advanced mutated 
disease [11].
The purpose of this observational retrospective 
cohort study was to assess differences in overall survival 
(OS) rates in patients with histologically diagnosed lung 
adenocarcinoma harboring either the most frequently 
detected or niche somatic mutations, to highlight new 
aspects to consider for prognosis and treatment. Considering 
the potential aggressiveness of niche mutations in this 
context, the technological advances of next-generation 
sequencing (NGS), which is currently used in clinical 
practice, represents a precise approach to identifying a large 
panel of mutations in oncologic patients [12].
RESULTS
Description of patients
Data were gathered from 252 patients. The clinical 
and demographic characteristics of the studied patients are 
reported in Table 1. The average age was 67.3 ± 9.9 years, 
63.5% of patients were male, and 82.5% of them were 
smokers. The majority of patients had been diagnosed with 
stage IV (63.1%) or III (19.0%) cancer according to the 
TNM (8th Edition). Patients were divided into three groups 
as follows: 42 (16.7%) patients in the niche mutations 
group, 155 (61.5%) in the KRAS group, and 55 (21.8%) 
in the EGFR group. We found differences in distributions 
of gender and smoking habits among the three cohorts. 
Male patients and smokers were more common in the 
KRAS group (74.8% males and 90.3% smokers) than 
in the niche mutations group (61.9% and 81.0%) or the 
EGFR mutation group (32.7% and 61.8%) (p = 0.000 
and p = 0.000). Moreover, the cohorts received different 
treatments because the frequency of chemotherapy and 
target therapy was not similar between the groups. In the 
KRAS groups, chemotherapy was performed on 79.4% 
of the patients, whereas chemotherapy was performed 
on 69.0% and 38.2% of patients in the niche mutations 
and EGFR mutations groups, respectively (p = 0.000). 
However, target therapy was more common in the EGFR 
mutation group (52.7%) than in the KRAS mutation 
(0.0%) and niche mutations (7.1%) groups (p = 0.000). 
The three cohorts were similar in terms of the remaining 
characteristics (i. e., age (p = 0.376), TNM stage (p = 
0.078), surgery (p = 0.940), radiotherapy (p = 0.462), 
and immunotherapy (p = 0.409). The most common 
first-line treatment was chemotherapy for the KRAS and 
niche mutations cohorts (53.5% and 42.9% of patients, 
respectively), whereas in the EGFR cohort, target therapy 
was more common (29.1% of patients). Eight (3.2%) 
patients did not undergo any treatment after diagnosis. The 
characteristics of patients harboring every single-niche 
mutation are reported in Supplementary Table 1.
Description of mutations
The observed distribution of single mutations is 
reported in Table 2. The most frequent mutation was 
found in the KRAS gene (found in 63.5% of the patients), 
whereas EGFR gene mutations were observed in 22.6% 
of the patients. In the niche mutations group, BRAF gene 
mutations were observed in 6.7% of the patients, whereas 
HER2 mutations were observed in 4.4% of the patients, 
PIK3CA gene mutations were detected in 4.0% of the 
patients and NRAS in 1.6%. No c-MET, DDR2, MAP2K1, 
or RET mutations were identified in any patient included 
in the study. Seven patients (2.8%) showed concomitant 
mutations in two genes and were all classified in the niche 
mutations cohort. The specific codons, exons, and amino 
acid alterations identified are reported in detail in Table 2.
Mortality rates
Over an average follow-up period of 1.3 (range 
0.1 to 4.8) years, there were 168 (66.7%) deaths, 167 of 
which were cancer-related. In the niche mutations cohort, 
29 (69.0%) patients died, in the KRAS gene cohorts 109 
(70.3%) died, and in the EGFR gene cohort 30 (54.5%) 
died.
MRs for each gene mutation and cohort considered 
are reported in Figure 1. Patients with KRAS mutations 
had an MR of 0.59 (95% CI = 0.49–0.71) deaths per year, 
whereas the MRs were 0.31 (0.21–0.44) for EGFR gene 
patients, 0.54 (0.29–0.98) for BRAF gene patients, 0.42 
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(0.15–0.91) for HER2 gene patients, 0.69 (0.30–1.35) for 
PIK3CA gene patients, and 0.60 (0.12–0.74) for NRAS 
gene patients. The subjects with two mutations presented 
an MR of 0.70 (0.26–1.53). The mortality was higher in 
the KRAS gene cohort (MR = 0.58, 95% CI = 0.48–0.70) 
and in the niche mutations cohort (MR = 0.55, 95% CI 
= 0.37–0.78) than in the EGFR gene cohort (MR = 0.31, 
95% CI = 0.21–0.44).
Differences in overall survival
The survival curves for the three cohorts are shown 
in Figure 2. The median OS was measured as 1.5 years 
(95% CI = 1.2–1.8) for the whole population, 1.5 years 
(95% CI = 0.8–2.3) for the niche mutations cohort, 1.3 
(95% CI = 1.0–1.6) years for the KRAS gene cohort, 
and 2.2 years (95% CI not estimable) for the EGFR 
gene cohort. The cumulative survival probability at 1 
year from diagnosis was measured as 56.5% (95% CI 
= 49.1–65.0%) for the KRAS gene mutation cohort, as 
60.1% (46.6–77.6%) for the niche mutations cohort, and 
as 69.2% (57.7–83.1%) for the EGFR gene mutations 
cohort, whereas at 2 years these values were measured as 
28.4% (21.2–38.0%), 38.2% (24.9–58.6%), and 58.2% 
(45.8–73.8%), respectively.
The differences in OS observed between the 
three cohorts of interest are reported in Figure 3 from 
the unadjusted and multivariable regression analyses. 
According to the multivariable analysis that adjusted 
for age, sex, smoking habits, stage, and treatments, we 
observed that 1) patients with niche mutations had a higher 
risk of death than patients with EGFR gene mutations (HR 
= 2.3; 95% CI = 1.2–4.4; p = 0.009); 2) patients with KRAS 
gene mutations had a higher risk of death than patients 
with EGFR gene mutations (HR = 2.5; 95% CI = 1.4–4.5; 
p = 0.003); 3) patients with niche mutations presented 
a risk of death similar to patients with KRAS gene 
mutations (HR = 0.9; 95% CI = 0.6–1.5; p = 0.797). These 
results did not change when patients with concomitant 
mutations were excluded or when patients with stage I or 
II diagnoses were excluded (Figure 3). The associations 
between all the recorded independent variables and 
the risk of death, as assessed by the Cox multivariable 
model, are reported in Supplementary Table 2. 
Table 1: Patients characteristics at primary diagnosis and treatments after diagnosis




All patients  
(n = 252) p-value
Patients characteristics at primary diagnosis
Age – Years mean ± SD 67.4 ± 9.4 65.9 ± 12.1 68.8 ± 8.4 67.3 ± 9.9 0.376
Gender – M n (%) 116 (74.8%) 18 (32.7%) 26 (61.9%) 160 (63.5%) 0.000
Smoker – Yes n (%) 140 (90.3%) 34 (61.8%) 34 (81.0%) 208 (82.5%) 0.000
Stage - I n (%) 9 (5.8%) 8 (14.5%) 1 (2.4%) 18 (7.1%)
0.078
Stage – II n (%) 18 (11.6%) 5 (9.1%) 4 (9.5%) 27 (10.7%)
Stage – III n (%) 27 (17.4%) 7 (12.7%) 14 (33.3%) 48 (19.0%)
Stage - IV n (%) 101 (65.2%) 35 (63.6%) 23 (54.8%) 159 (63.1%)
Treatments after diagnosis
Surgery n (%) 42 (27.1%) 16 (29.1%) 12 (28.6%) 70 (27.8%) 0.940
RT n (%) 75 (48.4%) 27 (49.1%) 25 (59.5%) 127 (50.4%) 0.462
CT n (%) 123 (79.4%) 21 (38.2%) 29 (69.0%) 173 (68.7%) 0.000
IMT n (%) 36 (23.2%) 8 (14.5%) 8 (19.0%) 52 (20.6%) 0.409
TT n (%) 0 (0.0%) 29 (52.7%) 3 (7.1%) 32 (12.7%) 0.000
First line treatment
Surgery n (%) 35 (22.6%) 12 (21.8%) 9 (21.4%) 56 (22.2%)
0.000
RT n (%) 27 (17.4%) 8 (14.5%) 7 (16.7%) 42 (16.7%)
CT n (%) 83 (53.5%) 12 (21.8%) 18 (42.9%) 113 (44.8%)
IMT n (%) 6 (3.9%) 6 (10.9%) 3 (7.1%) 15 (6.0%)
TT n (%) 0 (0.0%) 16 (29.1%) 2 (4.8%) 18 (7.1%)
No treatment n (%) 4 (2.6%) 1 (1.8%) 3 (7.1%) 8 (3.2%)
RT: Radiotherapy; CT: Chemotherapy; IMT: Immunotherapy; TT: Target Therapy; SD: standard deviation.
Oncotarget553www.oncotarget.com
The proportional hazards assumption was verified for all 
HRs of interest (data not shown).
DISCUSSION
Our study reports a retrospective analysis on OS 
rates observed in patients with lung adenocarcinoma 
harboring somatic mutations either in EGFR and KRAS 
genes, or in less frequently studied genes, such as 
BRAF, PIK3CA, NRAS, and HER2 (niche mutations). 
In our work, we analyzed and described the clinical 
characteristics of the three cohorts of patients. From our 
data, male subjects and smokers were more common in 
the KRAS group than in the niche mutations and EGFR 
groups. Furthermore, target therapies were more common 
in the EGFR group, whereas chemotherapy was more 
common in the KRAS and niche mutations cohorts. This 
is justified by the fact that no specific target treatment has 
yet been developed for KRAS and niche mutations.
Regarding treatments given after diagnosis, we 
observed that our cohorts of patients were treated as 
previously described for general mutations [15, 16]. This 
is likely because niche mutations are poorly understood, 
especially in terms of biological characteristics and 
interactions. However, we believe that the percentage of 
patients harboring niche mutations suggests further study, 
in particular with respect to treatment strategies.
In our study, we underlined the importance of niche 
mutations in terms of OS relative to the most frequent 
general somatic mutations and for KRAS in particular, 
which is considered to be the most frequent and aggressive 
mutation in lung adenocarcinoma. EGFR and KRAS gene 
mutations are already recorded in the molecular report 
that an oncologist needs to provide “personalized” therapy 
Table 2: Mutations, codons, exons and amino acid alterations identified in the study population
Frequent mutations Niche mutations Overall
n % n % n %
KRAS single 
mutation 155 61.5% BRAF single mutation 16 6.3% KRAS 160 63.5%
Codon 12 136 54.0% Codon 469 4 1.6% EGFR 57 22.6%
G12C 70 27.8% Codon 600 6 2.4% BRAF 17 6.7%
G12V 27 10.7% Codon 466 3 1.2% HER2 11 4.4%
G12D 22 8.7% HER2 single mutation 10 4.0% PIK3CA 10 4.0%
G12A 15 6.0% Codon 775 & 776 ins YVMA 7 2.8% NRAS 4 1.6%
Codon 13 13 5.2% PIK3CA single mutation 6 2.4%
Concomitant 
mutations 7 2.8%
G13C 8 3.2% Codon 542 1 0.4%
Codon 61 6 2.4% Codon 545 1 0.4%
EGFR single 
mutation 55 21.8% NRAS single mutation 3 1.2%
Exon 19 16 6.3% Codon 61 1 0.4%
Codon del 746  
& 750 14 5.6% Concomitant mutations 7 2.8%
Exon 21 17 6.7% KRAS & PIK3CA 2 0.8%
Codon 858 13 5.2% EGFR & PIK3CA 2 0.8%
Exon 18 4 1.6% KRAS & BRAF 1 0.4%
Exon 20 3 1.2% KRAS & NRAS 1 0.4%
Exons 20 & 21 5 2.0% KRAS & HER2 1 0.4%
Exons 19 & 20 4 1.6%
Exons 18 & 20 2 0.8%
Exons 19 & 21 1 0.4%
Notes: Counts at different levels of details may differ. All identified exons and codons were reported and only amino acids 
alterations with absolute frequency ≥ 5 are shown. Mutations for which the codon was not identified are not considered in 
the table.
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Figure 1: Mortality rates for mutations and cohorts considered in the study. MR = mortality rate, expressed as the number of 
deaths per person-year. 95% CI = 95% confidence interval. N = number of patients. The plot reports mortality rates and 95% confidence 
intervals.
Figure 2: Survival curves in the KRAS, EGFR, and niche mutations cohorts. The red line represents the KRAS cohort, the 
purple line represents the EGFR cohort and the blue line represents the niche mutations cohort. The median survival times for the three 
cohorts are reported on the horizontal axis. The number of patients at risk at 0, 1, 2, 3, and 4 years from baseline is reported. Thick marks 
represent subjects lost to follow-up.
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Figure 3: Differences in overall survival among niche mutations cohort and frequent mutations cohorts. HR = hazard 
ratio; 95% CI = 95% confidence interval. (A) = main analysis - all patients. (B) = secondary analysis – only patients without concomitant 
mutations. (C) = secondary analysis – only patients with stage III–IV at diagnosis. Results from both unadjusted and multivariable Cox 
regression analysis are reported. The multivariable model was adjusted for age, sex, smoking habits, stage and treatments. The plots report 
hazard ratios and 95% confidence intervals.
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[17–20]. In addition to the mutations for which target 
therapies have been generally successful, for example, for 
the EGFR gene, there are still mutations without effective 
therapies, as for the KRAS and niche mutations. The 
scientific community has agreed on the fact that KRAS is 
one of the most aggressive mutations in terms of prognosis 
and survival because it exhibits a high mortality rate and 
there is no existing targeted treatment available [17, 18]. 
Our data described a similar OS for KRAS and niche 
mutations. This aspect is very interesting and needs to be 
further considered, although little has been published on 
niche mutations in lung cancer, probably because they are 
only observed in a small proportion of the population.
We first described a large cohort study analyzing 
niche mutations in adenocarcinoma of the lung and their 
prognostic role as compared with the more frequently 
diagnosed mutations. In the current scientific literature, 
many studies have described the occurrence of general 
somatic mutations in NSCLC, although some niche 
mutations, such as c-MET and RET in adenocarcinoma 
of the lung have been described in a few short reports 
[19–22], or in a larger population focusing on a single-niche 
mutation of PIK3CA [23–25]. We took into consideration 
different rare mutations observed in BRAF, PIK3CA, 
HER2, and NRAS detected with a total frequency equal 
to 16.7% of patients with lung adenocarcinoma harboring 
somatic mutations, which is not a negligible prevalence 
if transposed to the entire population. Moreover, niche 
mutations presented a high risk of death, accounting for 
55% of deaths in one person-year.
The most interesting and novel results that came out 
of this research were that 1) niche mutations showed very 
similar rates of survival as those of patients with KRAS 
gene mutation; 2) patients harboring niche or KRAS gene 
mutations showed a higher risk of mortality than those 
with EGFR gene mutations.
We know that mutations in the KRAS gene are the 
most aggressive, and for this reason, we highlighted the 
importance of evaluating these niche mutations through 
our results. The life expectancy of these patients was low 
and seemed to be very similar to that of patients with well-
established aggressive general mutations. These patients 
may benefit from the use of specific inhibitors such as 
dabrafenib/trametinib, which are used for BRAF v600E 
mutations [26].
Limitations
Finally, the present study has some limitations 
that should be discussed. First, the observational and 
retrospective nature of this study presents a risk of bias; 
however, adjustments made to the multivariable analysis 
protected against confounding bias due to the observed 
patient characteristics. Nevertheless, other unobserved 
factors may have biased our results. Second, even if we 
observed statistically significant differences in the OS 
between niche mutations and general mutations in a large 
set of consecutive patients enrolled over 5 years, another 
limitation relates to the low absolute number of patients 
with niche mutations that were present. Because of this, 
it was not possible properly to assess differences in OS 
between the single-niche mutations. Moreover, because 
c-MET, DDR2, MAP2K1, and RET gene mutations were 
not observed in this study, we cannot draw conclusions 
about the OS of patients harboring these niche mutations.
Taken together, these limitations highlight the 
need for an extended study to confirm our findings and 
to reduce further the uncertainty regarding the prognostic 
role of niche mutations.
MATERIALS AND METHODS
This retrospective cohort study was carried out 
in accordance with the STrengthening the Reporting 
of OBservational studies in Epidemiology (STROBE) 
statement [13].
Study population
All patients with lung adenocarcinoma identified 
at the Modena University Hospital between January 1, 
2013 and December 31, 2017, and for whom a molecular 
analysis of gene mutations was available were eligible for 
inclusion. Inclusion criteria were histologically diagnosed 
primary or metastatic adenocarcinoma of the lung, age at 
primary diagnosis between 18 and 90 years, presence of at 
least one of BRAF, c-MET, DDR2, EGFR, HER2, KRAS, 
MAP2K1, NRAS, PIK3CA, and RET gene mutations. 
Exclusion criteria were patients with wild-type genes, 
patients with an unknown tumor, squamous cell carcinoma 
of the lung, large-cell carcinoma of the lung, small-cell 
lung cancer, and neuroendocrine tumors of the lung.
All patients received standard treatments according 
to the current guidelines based on clinical stage and other 
relevant clinical factors.
Data collection
Data were retrospectively collected based on 
electronic hospital patient records. The following 
information was gathered: date of primary diagnosis; 
age at diagnosis (years); sex (M, F); clinical stage at 
diagnosis (TNM 8th Edition) [14]; smoking status at 
diagnosis (yes, no); treatments performed after diagnosis 
(surgery, chemotherapy, radiotherapy, immunotherapy, 
target therapy); first-line treatment; presence of BRAF, 
c-MET, DDR2, EGFR, HER2, KRAS, MAP2K1, NRAS, 
PIK3CA, or RET gene mutations and related codons; date 
and cause of death; date of last follow-up.
The somatic mutations that were considered were 
those detectable by our genotyping platform.
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Molecular analysis
Molecular analysis of gene mutations was performed 
for patients with advanced lung cancer or for early-stage 
surgical patients after recurrence.
DNA was extracted from 10 µm thick representative 
sections cut from formalin-fixed and paraffin-embedded 
blocks of each tumor sample containing at least 50% 
tumor cells. Extraction was performed with the QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany), and the DNA 
was quantified with Xpose NGS (Trinean NV, Gentbrugge, 
Belgium). Mutations were detected using the high-
throughput genotyping platform Sequenom MassARRAY® 
System (Sequenom, San Diego, CA, USA) and the 
Myriapod® Lung Status kit (Diatech Pharmacogenetics, 
Italy) following the manufacturers’ protocols. The 
molecular array allowed for the identification of the 
mutations of the BRAF, c-MET, DDR2, EGFR, HER2, 
KRAS, MAP2K1, NRAS, PIK3CA, and RET genes. In 
brief, 25 ng DNA of each specific primitive tumor was 
amplified through a multiplex polymerase chain reaction 
and then incorporated nucleotides were inactivated using 
shrimp alkaline phosphatase. A single-base extension 
reaction was performed using extension primers that 
hybridized immediately adjacent to the mutations and a 
custom mixture of nucleotides. Salts were removed using 
a cation exchange resin. Multiplexed reactions were 
spotted in SpectroCHIP II arrays, and DNA fragments 
were resolved with matrix-assisted laser desorption/
ionization–time-of-flight (MALDI–TOF) using a compact 
mass spectrometer (Sequenom, San Diego, CA, USA) 
with a detection limit of 5%. The data were evaluated 
using MassARRAY Typer analyzer software 4.0, which 
allowed the identification of mutated alleles by comparing 
the ratio of the wild-type peak of all suspected mutants.
Statistical analysis
Descriptive characteristics of the patients at the 
time of diagnosis were recorded. Continuous variables 
were recorded as mean ± standard deviation (SD) values, 
and categorical variables were recorded as absolute 
and percentage frequencies. Comparisons of group 
characteristics were drawn using analysis of variance and 
chi-square tests. OS was defined as the time span from 
diagnosis to death (all-cause mortality was considered). 
The OS of patients who were still alive at the end of 
the follow-up period were treated as censored survival 
times. The main aim of the analysis was to compare 
the OS of three cohorts of patients harboring: 1) niche 
mutations (BRAF, c-MET, DDR2, HER2, MAP2K1, 
NRAS, PIK3CA, or RET); 2) KRAS mutations; 3) EGFR 
mutations. The mortality rates (MRs) were calculated as 
the number of deaths per person-year. The OS curves were 
calculated using the Kaplan–Meier method. The pairwise 
differences in OS between the three cohorts of interest 
were assessed by means of a Cox proportional hazards 
regression model. The Cox model results were reported as 
hazard ratios (HRs) with 95% confidence interval (95% 
CI) from unadjusted analysis (i. e., with the cohort as 
the only independent variable) and from a multivariable 
analysis that adjusted for the confounding effects 
attributable to age (years); sex (M vs F); smoking habits 
(yes vs no); clinical stage (III, IV vs I–II) at diagnosis; 
and treatments after diagnosis (surgery, chemotherapy, 
radiotherapy, immunotherapy, and target therapy – all 
yes vs no). The proportional hazards assumption was 
validated by a graphical assessment of scaled Schoenfeld 
residuals. All statistical analyses were performed with R 
3.4.3 statistical software (The R Foundation for Statistical 
Computing, Wien) at the p < 0.05 significance level.
CONCLUSIONS
We found evidence of a higher risk of death for 
patients harboring niche mutations relative to patients 
with EGFR gene mutations, whereas the risk for patients 
with niche mutations was found to be comparable to that 
of patients harboring KRAS gene mutations. We may 
summarize this message in two points: 1. As soon as the 
molecular biologist is able to identify a niche mutation, 
it is necessary to highlight this in the patient report to 
set a targeted treatment that offers a better solution than 
chemotherapy for the patient; 2. The NGS technique, 
which is able to select a myriad of genes, is more useful 
for the oncologist who is conscious of the importance of 
considering niche mutations.
The correct selection of mutations will be helpful 
in terms of the greater efficacy of treatment in association 
with better prognosis and a higher quality of life for 
oncologic patients.
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